FLT3 and acute myeloid leukemia: FMS-like tyrosine kinase 3 (FLT3) inhibitors represent the new standard of care for patients with FLT3-mutant acute myeloid leukemia (AML), in both the first line and salvage settings [1,2,3,4,5].